FDA Bill: Senate v. House
This article was originally published in The Gray Sheet
Executive Summary
FDA user fee reauthorization and reform bills approved in the House and Senate have close alignment on many issues of relevance to the device industry, but also maintain some substantive differences, as outlined in the chart below.